Elisabeth Schorb

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 599 citations · Full text

Medicine, Immunology, Oncology +12

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2017 · 381 citations · Full text

Medicine, Immunology, Oncology +17

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

Kristina Fritsch, Benjamin Kasenda, Elisabeth Schorb et al. · Leukemia · 2016 · 183 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial

Gerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst et al. · The Lancet Haematology · 2016 · 169 citations

Medicine, Hematology, Oncology +15

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · Leukemia · 2022 · 162 citations · Full text

Medicine, Immunology, Oncology +16